scholarly journals Human Mesenchymal Stem Cell Transfusion Is Safe and Improves Liver Function in Acute-on-Chronic Liver Failure Patients

2012 ◽  
Vol 1 (10) ◽  
pp. 725-731 ◽  
Author(s):  
Ming Shi ◽  
Zheng Zhang ◽  
Ruonan Xu ◽  
Hu Lin ◽  
Junliang Fu ◽  
...  
Keyword(s):  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Liver Function ◽  
Liver Failure ◽  
Human Mesenchymal Stem Cell ◽  
Chronic Liver ◽  
Chronic Liver Failure

Hydrogel-Mediated Sustained Systemic Delivery of Mesenchymal Stem Cell-Derived Extracellular Vesicles Improves Hepatic Regeneration in Chronic Liver Failure

2019 ◽  
Vol 11 (41) ◽  
pp. 37421-37433 ◽  
Author(s):  
Soura Mardpour ◽  
Mohammad Hossein Ghanian ◽  
Hamid Sadeghi-abandansari ◽  
Saeid Mardpour ◽  
Abdoreza Nazari ◽  
...  
Keyword(s):  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Liver Failure ◽  
Extracellular Vesicles ◽  
Chronic Liver ◽  
Hepatic Regeneration ◽  
Systemic Delivery ◽  
Chronic Liver Failure

scholarly journals Mesenchymal Stem Cell Transplantation for Liver Cell Failure: A New Direction and Option

2018 ◽  
Vol 2018 ◽  
pp. 1-10
Author(s):  
Yantian Cao ◽  
Bangjie Zhang ◽  
Rong Lin ◽  
Qingzhi Wang ◽  
Jie Wang ◽  
...  
Keyword(s):  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Stem Cell Transplantation ◽  
Liver Failure ◽  
Cell Transplantation ◽  
Chronic Liver ◽  
Early Assessment ◽  
Chronic Liver Failure ◽  
Mesenchymal Stem Cell Transplantation ◽  
Beneficial Effects

Background and Aims. Mesenchymal stem cell transplantation (MSCT) became available with liver failure (LF), while the advantages of MSCs remain controversial. We aimed to assess clinical advantages of MSCT in patients with LF. Methods. Clinical researches reporting MSCT in LF patients were searched and included. Results. Nine articles (n=476) related with LF patients were enrolled. After MSCT, alanine aminotransferase (ALT) baseline decreased largely at half a month (P<0.05); total bilirubin (TBIL) baseline declined to a certain stable level of 78.57 μmol/L at 2 and 3 months (P<0.05). Notably, the decreased value (D value) of Model for End-Stage Liver Disease score (MELD) of acute-on-chronic liver failure (ACLF) group was higher than that of chronic liver failure (CLF) group (14.93 ± 1.24 versus 4.6 ± 5.66, P<0.05). Moreover, MELD baseline of ≥20 group was a higher D value of MELD than MELD baseline of <20 group with a significant statistical difference after MSCT (P=0.003). Conclusion. The early assessment of the efficacy of MSCT could be based on variations of ALT at half a month and TBIL at 2 and 3 months. And it had beneficial effects for patients with LF, especially in ACLF based on the D value of MELD.

Acute Liver Failure

2019 ◽  
pp. 264-269
Author(s):  
James Y. Findlay ◽  
Eelco F. M. Wijdicks
Keyword(s):  
Liver Disease ◽  
Liver Function ◽  
Liver Failure ◽  
Acute Liver Failure ◽  
Chronic Liver ◽  
Chronic Liver Failure ◽  
Underlying Liver Disease ◽  
Rapid Deterioration ◽  
Uncommon Condition ◽  
Acute Insult

Acute liver failure (ALF) is an uncommon condition in which an acute insult results in a rapid deterioration of liver function, encephalopathy, and coagulopathy in the absence of prior underlying liver disease. It is differentiated from rapid deterioration in the setting of underlying liver disease (acute on chronic liver failure) and from the gradual deterioration in liver function that can occur in chronic liver failure.

Sign in / Sign up

Export Citation Format

Share Document